Navigation Links
Thoratec Announces Resignation of Chief Financial Officer
Date:6/10/2011

PLEASANTON, Calif., June 10, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that David V. Smith, Executive Vice President and Chief Financial Officer, has resigned from his position in order to pursue other business opportunities.  Mr. Smith will remain with Thoratec through July 1st and assist in the transition process.

"Over the past several years, David has played a key role in building a world-class financial infrastructure at Thoratec, which positions the company well to support continued strong performance.  We thank him for his contributions and wish him well in his future endeavors," said Gary F. Burbach, President and Chief Executive Officer.

In conjunction with today's announcement, Thoratec is reiterating its previously issued 2011 financial guidance.

Roxanne Oulman, Vice President of Finance, will serve as interim Chief Financial Officer until a permanent replacement is named.  Ms. Oulman joined Thoratec in 2004 and has assumed increasing levels of responsibility since that time.  

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation.

Many of the preceding paragraphs, particularly but not exclusively those addressing guidance for fiscal 2011 financial results or future performance, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "projects," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new products and new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products and related gross margin for such product sales, the ability to improve financial performance, the effects of FDA regulatory requirements, our ability to address issues raised by FDA inspections adequately and on a timely basis without a results recall of products or interruption of manufacturing or shipment of products, the effects of healthcare reimbursement and coverage policies, the effects of seasonality on Thoratec product sales, the effects of competition and the effects of any merger, acquisition and divestiture related activities. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K, and in Thoratec's first quarter 2011 quarterly report on Form 10-Q and as may be updated in subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Announces Presentations at Upcoming Investor Conferences
2. Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology
3. Thoratec Presentation at Bank of America Conference to be Webcast
4. Thoratec Reports First Quarter 2011 Results
5. Thoratec Corporation Announces Redemption of Senior Subordinated Convertible Notes Due 2034
6. Thoratec Announces Presentations at Upcoming Investor Conferences
7. Thoratec Corporation Authorizes $100 Million Share Repurchase Program
8. Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations
9. Thoratec Schedules Fourth Quarter Conference Call, Webcast
10. Thoratec Presentation at J.P. Morgan Conference to Be Webcast
11. Thoratec Announces Webcast of Investor Presentation at American Heart Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/15/2017)... -- Enterin Inc., a Philadelphia -based biotechnology ... announced the completion of a $12.7 million Series A financing ... well as the participation of existing investors. ... support of New Ventures III and our current investors, and ... potential of our platform technology to transform the course of ...
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
Breaking Medicine Technology:
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... SignatureCare Emergency ... in the Austin, TX area 24 Hours a day. , The Emergency ... TX. , “We’ve been open four months now and things are running smoothly,” ...
(Date:7/24/2017)... Angeles, CA (PRWEB) , ... July 24, 2017 , ... ... will spotlight doctors and the cosmetic surgeries they perform on a daily basis. ... performing the cosmetic surgery procedures they specialize in at their practices. , When ...
(Date:7/24/2017)... ... 24, 2017 , ... The International Essential Tremor Foundation (IETF) will host a ... (ET). The seminar will take place on Saturday, Aug. 26 at the Embassy Suites ... will run from 9 a.m. to 12 p.m., with check-in beginning at 8 a.m. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... A CDC study shows that, although people ... of Caucasians (ages 18 to 29), had at least one case of sunburn within the ... time, which causes people to ignore the issue. However, only recently have people become conscientious ...
(Date:7/24/2017)... Atlanta, Georgia (PRWEB) , ... July 24, 2017 ... ... first comprehensive sleep management solution focused on delivering end-to-end sleep health ... (OSA) program. , Recent literature shows that adherence rates for positive airway pressure ...
Breaking Medicine News(10 mins):